JPWO2021011885A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021011885A5 JPWO2021011885A5 JP2022502205A JP2022502205A JPWO2021011885A5 JP WO2021011885 A5 JPWO2021011885 A5 JP WO2021011885A5 JP 2022502205 A JP2022502205 A JP 2022502205A JP 2022502205 A JP2022502205 A JP 2022502205A JP WO2021011885 A5 JPWO2021011885 A5 JP WO2021011885A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- cdr1
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962875416P | 2019-07-17 | 2019-07-17 | |
| US62/875,416 | 2019-07-17 | ||
| PCT/US2020/042573 WO2021011885A1 (en) | 2019-07-17 | 2020-07-17 | Claudin18 antibodies and methods of treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022541435A JP2022541435A (ja) | 2022-09-26 |
| JPWO2021011885A5 true JPWO2021011885A5 (ru) | 2023-07-26 |
Family
ID=74211179
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022502205A Pending JP2022541435A (ja) | 2019-07-17 | 2020-07-17 | クローディン１８抗体及びがんを処置する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20220372133A1 (ru) |
| EP (1) | EP3999548A4 (ru) |
| JP (1) | JP2022541435A (ru) |
| KR (1) | KR20220035414A (ru) |
| CN (1) | CN114364701A (ru) |
| AU (1) | AU2020313978A1 (ru) |
| BR (1) | BR112022000371A2 (ru) |
| CA (1) | CA3146665A1 (ru) |
| IL (1) | IL289663A (ru) |
| MX (1) | MX2022000652A (ru) |
| WO (1) | WO2021011885A1 (ru) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113645996B (zh) | 2019-02-01 | 2024-04-02 | 新石生物制药有限公司 | 抗claudin 18抗体及其使用方法 |
| EP3999548A4 (en) | 2019-07-17 | 2023-08-16 | The Regents of the University of California | CLAUDIN18 ANTIBODIES AND METHODS OF TREATMENT OF CANCER |
| US20240024498A1 (en) * | 2020-09-30 | 2024-01-25 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Pharmaceutical composition comprising antibody-drug conjugate, and use of pharmaceutical composition |
| IL305736A (en) | 2021-03-09 | 2023-11-01 | Xencor Inc | Heterodimeric antibodies that bind CD3 and CLDN6 |
| WO2022266219A1 (en) * | 2021-06-15 | 2022-12-22 | Xencor, Inc. | Heterodimeric antibodies that bind claudin18.2 and cd3 |
| WO2022268200A1 (zh) * | 2021-06-25 | 2022-12-29 | 信达生物制药(苏州)有限公司 | 针对密蛋白18.2的抗体及其用途 |
| KR20240044467A (ko) * | 2021-08-09 | 2024-04-04 | 하버 바이오메드 (상하이) 컴퍼니 리미티드 | Cldn18.2-표적화 항체, 이중특이적 항체, 및 이들의 용도 |
| WO2023196742A1 (en) * | 2022-04-08 | 2023-10-12 | Fred Hutchinson Cancer Center | Anti-cd90 antibodies, binding fragments, and uses thereof |
| WO2023232140A1 (en) * | 2022-06-03 | 2023-12-07 | Lanova Medicines Development Co., Ltd. | Cancer treatment with a pd-1 or pd-l1 inhibitor and an antibody-drug conjugates targeting claudin 18.2 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1997832A1 (en) * | 2007-05-29 | 2008-12-03 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against Claudin-18 for treatment of cancer |
| WO2014146672A1 (en) * | 2013-03-18 | 2014-09-25 | Ganymed Pharmaceuticals Ag | Therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2016165762A1 (en) * | 2015-04-15 | 2016-10-20 | Ganymed Pharmaceuticals Ag | Drug conjugates comprising antibodies against claudin 18.2 |
| CA3030257A1 (en) * | 2016-07-08 | 2018-01-11 | Carsgen Therapeutics Co., Ltd. | Antibody for anti-claudin 18a2 and use thereof |
| WO2018054484A1 (en) * | 2016-09-23 | 2018-03-29 | Biontech Ag | Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases |
| AU2019314999A1 (en) * | 2018-08-03 | 2021-02-11 | Amgen Inc. | Antibody constructs for CLDN18.2 and CD3 |
| CN109762067B (zh) * | 2019-01-17 | 2020-02-28 | 北京天广实生物技术股份有限公司 | 结合人Claudin 18.2的抗体及其用途 |
| EP3999548A4 (en) | 2019-07-17 | 2023-08-16 | The Regents of the University of California | CLAUDIN18 ANTIBODIES AND METHODS OF TREATMENT OF CANCER |
-
2020
- 2020-07-17 EP EP20839947.7A patent/EP3999548A4/en active Pending
- 2020-07-17 JP JP2022502205A patent/JP2022541435A/ja active Pending
- 2020-07-17 MX MX2022000652A patent/MX2022000652A/es unknown
- 2020-07-17 WO PCT/US2020/042573 patent/WO2021011885A1/en unknown
- 2020-07-17 US US17/627,540 patent/US20220372133A1/en active Pending
- 2020-07-17 KR KR1020227004165A patent/KR20220035414A/ko not_active Application Discontinuation
- 2020-07-17 BR BR112022000371A patent/BR112022000371A2/pt unknown
- 2020-07-17 CN CN202080062500.1A patent/CN114364701A/zh active Pending
- 2020-07-17 AU AU2020313978A patent/AU2020313978A1/en active Pending
- 2020-07-17 CA CA3146665A patent/CA3146665A1/en active Pending
-
2022
- 2022-01-06 IL IL289663A patent/IL289663A/en unknown
- 2022-10-03 US US17/959,104 patent/US11834499B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Strohl | Current progress in innovative engineered antibodies | |
| JP6708635B2 (ja) | ＣＤ３εおよびＲＯＲ１に対する二特異性抗体 | |
| JP2019519492A5 (ru) | ||
| WO2015063187A1 (en) | Multivalent antigen-binding proteins | |
| WO2017059387A1 (en) | Binding molecules with modified j-chain | |
| AU2016233495A2 (en) | Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof | |
| EP3816185A1 (en) | Multispecific antibody directed against pd-l1 and a tumor-associated antigen | |
| JPWO2019129221A5 (ru) | ||
| US20230391882A1 (en) | Combination treatment | |
| US20200216539A1 (en) | Bispecific anti pd1-anti tim3 antibodies | |
| CN114641504A (zh) | 抗b7h4抗体及其双抗和应用 | |
| EP3892639A1 (en) | Cd3 antibody and pharmaceutical use thereof | |
| CN116745317A (zh) | 抗tigit抗体及其用途 | |
| CN113574069A (zh) | 抗pd-l1抗体及其用途 | |
| JPWO2021011885A5 (ru) | ||
| US20230114801A1 (en) | MINIATURE GUIDANCE AND NAVIGATION CONTROL (miniGNC) ANTIBODY-LIKE PROTEINS AND METHODS OF MAKING AND USING THEREOF | |
| US20230002488A1 (en) | Guidance and navigation control proteins and method of making and using thereof | |
| JP2024001073A5 (ru) | ||
| JPWO2019195452A5 (ru) | ||
| JPWO2020191344A5 (ru) | ||
| JP2023530766A (ja) | 二重特異性抗体及びその用途 | |
| CN115776897A (zh) | 具有H2L2与HCAb结构的结合蛋白 | |
| KR20240055080A (ko) | Pd-1에 특이적으로 결합하는 단백질 및 그의 약학적 용도 | |
| JP2023530720A (ja) | Ｌｅｗｉｓ Ｙに対するヒト化抗体 | |
| CN118076387A (zh) | 靶向表达cdh17的肿瘤的多特异性抗体及其制备和使用方法 |